Looking Ahead: What's Next for Hematology/Oncology in 2022?
Oncology
; 2022.
Article
in English
| ProQuest Central | ID: covidwho-2305364
ABSTRACT
[...]because of the pandemic, many centers are experiencing staffing shortages in their clinical trial offices, leading to longer times for opening trials and, in some cases, halting new enrollments. Tixagevimab in combination with cilgavimab (Evusheld) is a new SARS-CoV-2 spike protein-directed attachment inhibitor that has gained emergency use authorization for individuals who are moderately to severely immunocompromised because of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination. Clinical trials of this monoclonal antibody combination showed a reduction in symptomatic SARS-CoV-2 illness as well as severe illness or death in the treatment arm.
Search on Google
Collection:
Databases of international organizations
Database:
ProQuest Central
Language:
English
Journal:
Oncology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS